RGNX - REGENXBIO Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 51.65B
Enterprise Value 31.32B
Trailing P/E N/A
Forward P/E 1-154.28
PEG Ratio (5 yr expected) 1-9.10
Price/Sales (ttm)25.68
Price/Book (mrq)3.52
Enterprise Value/Revenue 320.49
Enterprise Value/EBITDA 6-13.20

Trading Information

Stock Price History

Beta (3Y Monthly) 0.79
52-Week Change 3-18.22%
S&P500 52-Week Change 318.19%
52 Week High 363.21
52 Week Low 330.38
50-Day Moving Average 339.04
200-Day Moving Average 341.36

Share Statistics

Avg Vol (3 month) 3565.07k
Avg Vol (10 day) 3581.46k
Shares Outstanding 536.87M
Float 26.5M
% Held by Insiders 115.70%
% Held by Institutions 183.65%
Shares Short (Nov. 15, 2019) 44.29M
Short Ratio (Nov. 15, 2019) 48.36
Short % of Float (Nov. 15, 2019) 415.17%
Short % of Shares Outstanding (Nov. 15, 2019) 411.62%
Shares Short (prior month Oct. 15, 2019) 44.52M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 31, 2018
Most Recent Quarter (mrq)Sep. 30, 2019

Profitability

Profit Margin -99.57%
Operating Margin (ttm)-165.35%

Management Effectiveness

Return on Assets (ttm)-12.96%
Return on Equity (ttm)-13.29%

Income Statement

Revenue (ttm)64.24M
Revenue Per Share (ttm)1.76
Quarterly Revenue Growth (yoy)177.00%
Gross Profit (ttm)124.99M
EBITDA -99.68M
Net Income Avi to Common (ttm)-63.96M
Diluted EPS (ttm)-1.75
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)331.72M
Total Cash Per Share (mrq)9
Total Debt (mrq)6.83M
Total Debt/Equity (mrq)1.46
Current Ratio (mrq)11.49
Book Value Per Share (mrq)12.71

Cash Flow Statement

Operating Cash Flow (ttm)-86.34M
Levered Free Cash Flow (ttm)-55.59M